ATE432292T1 - Antitumorantikörper, proteine und deren verwendung - Google Patents

Antitumorantikörper, proteine und deren verwendung

Info

Publication number
ATE432292T1
ATE432292T1 AT00948759T AT00948759T ATE432292T1 AT E432292 T1 ATE432292 T1 AT E432292T1 AT 00948759 T AT00948759 T AT 00948759T AT 00948759 T AT00948759 T AT 00948759T AT E432292 T1 ATE432292 T1 AT E432292T1
Authority
AT
Austria
Prior art keywords
antibodies
antitumorant
proteins
expressed
disclosed
Prior art date
Application number
AT00948759T
Other languages
English (en)
Inventor
Kenneth Rock
Dancella Fernandes
Original Assignee
Univ Massachusetts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Massachusetts filed Critical Univ Massachusetts
Application granted granted Critical
Publication of ATE432292T1 publication Critical patent/ATE432292T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT00948759T 1999-07-23 2000-07-18 Antitumorantikörper, proteine und deren verwendung ATE432292T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14533799P 1999-07-23 1999-07-23
PCT/US2000/019589 WO2001007481A1 (en) 1999-07-23 2000-07-18 Antitumor antibodies, proteins, and uses thereof

Publications (1)

Publication Number Publication Date
ATE432292T1 true ATE432292T1 (de) 2009-06-15

Family

ID=22512634

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00948759T ATE432292T1 (de) 1999-07-23 2000-07-18 Antitumorantikörper, proteine und deren verwendung

Country Status (21)

Country Link
EP (1) EP1200476B1 (de)
JP (2) JP4842476B2 (de)
KR (1) KR20020034164A (de)
CN (1) CN1390233A (de)
AT (1) ATE432292T1 (de)
AU (1) AU6221200A (de)
BR (1) BR0012704A (de)
CA (1) CA2380066C (de)
CZ (1) CZ303771B6 (de)
DE (1) DE60042273D1 (de)
ES (1) ES2327894T3 (de)
HU (1) HU229416B1 (de)
IL (2) IL147810A0 (de)
MX (1) MXPA02000846A (de)
NO (1) NO329234B1 (de)
NZ (2) NZ530390A (de)
PL (1) PL204822B1 (de)
PT (1) PT1200476E (de)
RU (1) RU2002104713A (de)
WO (1) WO2001007481A1 (de)
ZA (1) ZA200200856B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US6693176B1 (en) 1999-07-23 2004-02-17 University Of Massachusetts Antitumor antibodies, proteins, and uses thereof
PL204822B1 (pl) * 1999-07-23 2010-02-26 Univ Massachusetts Izolowane przeciwciało, wiążące antygen fragmenty tego przeciwciała, linia komórkowa hybrydomy, kompozycja farmaceutyczna zawierająca izolowane przeciwciało, zastosowanie izolowanego przeciwciała, zestaw zawierający izolowane przeciwciało oraz środek ukierunkowany na komórki nowotworowe zawierający izolowane przeciwciało
DE10016025B4 (de) 2000-03-31 2005-06-16 Hde Solutions Gmbh Verfahren zur Herstellung von Hohlkörpern
US7935338B2 (en) * 2001-12-11 2011-05-03 University Of Massachusetts Antibodies to treat cancer
CN1468956A (zh) * 2002-07-15 2004-01-21 杨 琴 高效表达治疗肿瘤的抗体的重组病毒及其用途
US20040115204A1 (en) 2002-12-11 2004-06-17 Fanger Gary R. Antibodies to treat cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU617295B2 (en) * 1986-11-13 1991-11-28 Sloan-Kettering Institute For Cancer Research Compositions and method for treatment of cancer using monoclonal antibody against gd3 ganglioside together with il-2
US5104652A (en) * 1986-11-13 1992-04-14 Sloan-Kettering Institute For Cancer Research Compositions and method for treatment of cancer using monoclonal antibody against GD3 ganglioside together with IL-2
PL204822B1 (pl) * 1999-07-23 2010-02-26 Univ Massachusetts Izolowane przeciwciało, wiążące antygen fragmenty tego przeciwciała, linia komórkowa hybrydomy, kompozycja farmaceutyczna zawierająca izolowane przeciwciało, zastosowanie izolowanego przeciwciała, zestaw zawierający izolowane przeciwciało oraz środek ukierunkowany na komórki nowotworowe zawierający izolowane przeciwciało

Also Published As

Publication number Publication date
MXPA02000846A (es) 2002-10-23
NO20020329D0 (no) 2002-01-22
PT1200476E (pt) 2009-08-10
ZA200200856B (en) 2003-07-30
CA2380066C (en) 2011-07-05
DE60042273D1 (de) 2009-07-09
JP4842476B2 (ja) 2011-12-21
IL187595A (en) 2013-05-30
AU6221200A (en) 2001-02-13
HU229416B1 (en) 2013-12-30
EP1200476A4 (de) 2004-11-17
NO329234B1 (no) 2010-09-20
WO2001007481A1 (en) 2001-02-01
PL204822B1 (pl) 2010-02-26
WO2001007481A9 (en) 2002-08-29
CA2380066A1 (en) 2001-02-01
PL353872A1 (en) 2003-12-01
ES2327894T3 (es) 2009-11-05
EP1200476B1 (de) 2009-05-27
HUP0202270A3 (en) 2012-09-28
IL147810A0 (en) 2002-08-14
RU2002104713A (ru) 2003-08-27
NZ516771A (en) 2004-02-27
NO20020329L (no) 2002-02-25
EP1200476A1 (de) 2002-05-02
CN1390233A (zh) 2003-01-08
BR0012704A (pt) 2002-07-02
CZ303771B6 (cs) 2013-05-02
CZ2002288A3 (cs) 2002-06-12
JP2003508525A (ja) 2003-03-04
KR20020034164A (ko) 2002-05-08
JP2011219477A (ja) 2011-11-04
HUP0202270A2 (en) 2002-10-28
NZ530390A (en) 2005-09-30
IL187595A0 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
BG103251A (bg) Оксадиазоли, методи за получаването им и приложението им като лекарствени средства
ATE267255T1 (de) Ob proteinderivate mit verlängerter halbwertzeit
ATE403680T1 (de) Herstellung tetravalenter antikörper
ATE239797T1 (de) Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
DE69623472D1 (de) Derivate von dolastatin, dreen herstellung un verwendung
ES2123973T3 (es) Afamina: una proteina similar a la seroalbumina humana.
DE69735502D1 (de) Mutanten des lag-3 proteins, ihre expression und verwendung
IL187595A0 (en) Antitumor antibodies, proteins, and uses thereof
ATE183195T1 (de) Isolierte, von mage-3 abgeleitete peptide, welche mit hla-a2 molekülen komplexieren
ATE152734T1 (de) Bpc-peptide, deren herstellung und verwendung
NO971341D0 (no) Promoter for reseptor tyrosinkinase TIE
EP0163304A3 (de) Menschliche monoklonale Antikörper gegen Zwischenfäden
DE69737651D1 (de) Cortistatin: neuropeptide, zusammensetzungen und methoden
EP0875567A3 (de) Myc-bindende Zinkfinger-Proteine, ihre Herstellung und ihre Verwendung
BG101038A (bg) Супресия на растежа на туморни клетки посредствомсиндекан- 1 ектоучастък
DE69634077D1 (de) Haemophilus adhäsionsproteinen
DK0939769T3 (da) Vertebrat-Smoothened-proteiner
SE9802507D0 (sv) Novel salts
ATE40116T1 (de) 1-acyl-3-pyridylmethylguanidine und deren verwendung als antihypertensiva.
DE69627279D1 (de) Gelierungsbeschleuniger, einen diesen beinhaltenden Injektionsschlamm und dessen Verwendung
ATE298244T1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf- erkrankungen
ID27656A (id) Turunan azabisikloheptana n-tersubstitusi, pembuatan dan penggunaannya
ATE309371T1 (de) Protein mit dnase-aktivität
SE9604439D0 (sv) New receptor
IT1301815B1 (it) Anticorpi monoclonali umani contro l'antigene tumorale uk114 e cellulelinfocitarie e ibridomi per la loro produzione

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1200476

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 1200476

Country of ref document: EP